The US FDA has approved Galderma's Nemluvio (nemolizumab), for individuals aged 12 years and above with moderate-to-severe atopic dermatitis.
The biopharmaceutical industry faces a future full of risks and rewards. But what role will 3PL suppliers play?
Boehringer Ingelheim’s blockbuster Ofev could be set for an expanded indication in children and adolescents with fibrosing ILDs.
New HTA statistics produced by Denmark’s Medicinrådet for 2024 have prompted GlobalData to assess evolving HTA trends in the Nordic market.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Omvoh (mirikizumab) for approval in the European Union (EU) to treat adults with ...
WuXi AppTec and WuXi Biologics are looking to sell off sites in the US and Europe as the prospect of the Biosecure Act is deterring potential clients.
Discover the latest advancements in small cell lung cancer through Novotech CRO’s in-depth disease analysis. Gain valuable insights into novel therapies, ongoing clinical trials, and future ...
AbbVie has entered into a definitive agreement to acquire Nimble Therapeutics in a deal valued at $200m in cash.
RMC-9805 is a small molecule commercialized by Revolution Medicines, with a leading Phase I program in Colorectal Cancer.
PM-359 is a gene-modified cell therapy commercialized by Prime Medicine, with a leading Phase II program in Chronic Granulomatous Disease.
NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders.
Risk adjusted net present value: What is the current valuation of Artiva Biotherapeutics’s GCC-4001?
GCC-4001 is a cell therapy commercialized by Artiva Biotherapeutics, with a leading Phase II program in B-Cell Non-Hodgkin Lymphoma.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback